<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">123147</article-id><article-id pub-id-type="doi">10.23868/gc123147</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Stem Cells Business</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hematopoietic progenitors mobilization market: Is there time to change?</article-title><trans-title-group xml:lang="ru"><trans-title>Рынок препаратов для мобилизации гемопоэтических предшественников: время перемен?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurtova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Куртова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>info@eco-vector.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Laboratory of Clinical Immunology and Molecular Diagnostics, Pavlov state Medical University</institution></aff><aff><institution xml:lang="ru">Лаборатория клинической иммунологии и молекулярной диагностики, Санкт-Петербургский Государственный Медицинский Университет им. акад. И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2007-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2007</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>75</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2023-01-17"><day>17</day><month>01</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-01-17"><day>17</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2007, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2007, Эко-Вектор</copyright-statement><copyright-year>2007</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/123147">https://genescells.ru/2313-1829/article/view/123147</self-uri><abstract xml:lang="en"><p>The purpose of this review is to perform a comprehensive comparative analysis of different hematopoietic progenitor’s mobilizers with short excursus to mobilizers’ market development. Special attention is paid to the new drugs with great clinical perspectives.</p></abstract><trans-abstract xml:lang="ru"><p>В работе представлен обзор основных препаратов для мобилизации гемопоэтических предшественников с кратким анализом развития рынка данных услуг. Особое внимание уделено новым препаратам для мобилизации с перспективами широкого клинического применения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>mobilization</kwd><kwd>HSC</kwd><kwd>oncohematology</kwd><kwd>regeneration therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мобилизация</kwd><kwd>ГСК</kwd><kwd>онкогематология</kwd><kwd>регенерационная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Appelbaum F.R. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. Cancer J. Clin. 1996; 46: 142-64.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>To L.B., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood 1997; 89(7): 2233-58.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kessinger A., McMannis J. Practical consideration of apheresis in peripheral blood stem cell transplantation. 1st ed. Lakewood: COBE Inc; 1994.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hoglund M. Glycosylated and non-glycosylated rhG-CSF - what is the difference? Med. Oncol. 1998; 15: 229-33.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Martin-Christin F. Granulocyte colony-stimulating factors: how different are they? How to make a decision? Anti-Cancer Drugs 2001 ; 12: 185-91.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Morris E.S., MacDonald K.P.A., Rowe V. et al. Donor treatment with pegylated G-CSF augments the generation of IL-10 producing regulatory T cells and promotes transplant tolerance. Blood 2004; 103: 3573-81.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nowrousian M.R., Waschke S., Bojko P. et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann. Oncol. (Suppl) 2003; 14: i29-36.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>http://www.clinicaltrials.gov/ct/show/NCT00208949?order=31</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Facon T., Harousseau J.L., Maloisel F. et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized clinical trial. Blood 1999; 94(4): 1218-25.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Liles W.C., Broxmeyer H., Rodger E. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102(8): 2728-30.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Urbano-Ispizua A. Risk assessment in hematopoietic stem cells transplantation: stem cell source. Best Pract. Res. Clin. Haematol. 2007; 20(2): 265-80.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>www.cancer.gov</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>DiPersio J.F., Shuster M.W., Abboud C.N. et al. Mobilization of PBSC by concurrent administration of daniplestim and G-CSF in patients with breast cancer and lymphoma. J. Clin. Oncol. 2000; 18: 2762-71.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bishop M.R., Jackson J.D., O'Kane-Murphy B. et al. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J. Clin. Oncol. 1996; 14: 2521-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Morris E.S., MacDonald K.P., Rowe V. et al. Stem cell mobilization with novel G-CSF analogues augment NKT cell restricted graft-versus-leukemia effects. Biol. Blood Marrow Transpl. 2005: 11 (2; Sup.1): 45 (abstract 133).</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Carlo-Stella C., Di Nicola M., Milani R. et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-95.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ballen K., Shpall E.J., Avigan D. et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol. Blood Marrow Transpl. 2007; 13(7): 838-43.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zohlnhofer D., Ott I., Mehilli J. et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295(9):1003-10.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>http://www.stemcellsummit.com/book-tour/index.html</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>http://www.genzyme.com/corp/media/GENZ%20PR-080207.asp</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>http://www.genzyme.com/corp/investors/GENZ%20PR- 071907.asp</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Copelan E.A. Hematopoietic stem cell transplantation. NEJM 2006; 354: 1813-26.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>www.clinicaltrials.gov</mixed-citation></ref></ref-list></back></article>
